Why Can Some MS Treatments Worsen Relapses in NMOSD?

Important Safety Warning: If you are currently taking a medication for Multiple Sclerosis (MS) and suspect you may have Neuromyelitis Optica Spectrum Disorder (NMOSD), do not stop taking your medication on your own. Abruptly stopping certain MS drugs, particularly fingolimod, can trigger severe rebound attacks ^[1]. Contact your prescribing neurologist promptly to plan a safe evaluation and, if necessary, a supervised medication transition.

If you have NMOSD, treating it with certain medications designed for MS can be harmful. While NMOSD and MS share overlapping symptoms like vision loss and paralysis, they are distinct diseases with different underlying biology. Observational studies and clinical reports suggest that specific MS drugs—particularly interferon-beta, natalizumab, and fingolimod—are ineffective at preventing NMOSD relapses and may worsen the disease ^{[2] [3]}.

Distinct Diseases with Different Mechanisms

To understand why some MS drugs fail in NMOSD, it helps to understand what drives each disease.

• Multiple Sclerosis is a complex inflammatory disease involving multiple types of immune cells (including T-cells and B-cells) that attack myelin, the protective coating around nerve fibers.
• NMOSD, particularly the AQP4-IgG positive type, is primarily an astrocytopathy—a disease that targets astrocytes, which are support cells in the central nervous system ^[4].

In most adults with confirmed NMOSD, the immune system produces an autoantibody called AQP4-IgG ^[4]. These antibodies bind to astrocytes and activate the complement system (a cascade of immune proteins), leading to astrocyte destruction and secondary damage to the nervous system ^[5].

Because many traditional MS drugs were developed to target different inflammatory pathways, they have not been shown to prevent the AQP4-IgG antibodies and complement system from causing damage in NMOSD ^[3].

Proposed Reasons Why Specific MS Drugs Worsen NMOSD

While leaving NMOSD untreated poses a high risk of relapse, certain MS drugs have been associated with severe attacks in NMOSD patients ^[2]. Researchers have proposed several hypotheses for why this happens based on case reports and experimental models.

B-Cell Alterations (Interferon-beta and Natalizumab)

NMOSD is heavily driven by B-cells, the immune cells that help produce the harmful AQP4-IgG antibodies ^[3]. Researchers propose that MS treatments like interferon-beta and natalizumab might inadvertently alter B-cell behavior or cause B-cells to accumulate in the bloodstream ^{[3] [6]}. In theory, this could increase the immune activity that fuels NMOSD, though this remains a proposed explanation rather than a proven cause for every patient.

Additionally, experimental animal models suggest that natalizumab might disrupt protective signaling between blood vessels and astrocytes, potentially making astrocyte damage worse ^[7]. In small clinical observations, NMOSD patients given natalizumab experienced relapses and worsened disability ^[8].

Immune Cell Trapping and Rebound (Fingolimod)

Fingolimod works by trapping immune cells inside lymph nodes so they cannot travel to the brain. Clinical case series have shown this mechanism does not adequately control NMOSD relapses ^[9]. More concerningly, if a patient with NMOSD abruptly stops taking fingolimod, they are at risk for a severe “rebound” relapse. Case reports have documented fulminant, sometimes fatal, attacks occurring shortly after fingolimod was discontinued ^[1]. This is why supervised medical transitions are strictly required.

Accurate Diagnosis and Targeted Treatments

Because specific MS drugs can exacerbate your condition, ensuring an accurate diagnosis is critical. A proper evaluation typically involves an AQP4-IgG blood test, MRI scans, and a review of your clinical history ^[2]. Some patients may test positive for a different antibody (MOG-IgG), which indicates a separate condition called MOG-Antibody Disease (MOGAD) that requires its own tailored management.

If you have AQP4-IgG positive NMOSD, several FDA-approved treatments are specifically designed for adults with this condition:

• B-cell targeting therapies (such as inebilizumab) that reduce the populations of B-cells responsible for the disease ^[10].
• Complement inhibitors (such as eculizumab and ravulizumab) that block the destructive immune cascade ^{[10] [11]}. Note: These medications carry a serious risk of meningococcal infection and require specialized vaccinations and strict monitoring.
• IL-6 receptor blockers (such as satralizumab) that reduce the inflammatory signaling driving the disease ^[10].

Seeking Urgent Care: These approved medications are for preventing relapses, not treating an active attack. If you experience new or worsening vision loss, weakness, numbness, difficulty walking, bladder issues, or persistent hiccups/vomiting, seek urgent medical evaluation immediately.

If you are diagnosed with NMOSD while taking an MS medication, your specialist will create an individualized plan to transition you to an appropriate therapy safely, balancing the risks of your current medication with the risks of a rebound attack.